losartan, hydrochlorothiazide

ApprovedSmall molecule

losartan, hydrochlorothiazide is one of 49 small molecule programs targeting Essential Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

HypertensionActive, not recruiting

Essential HypertensionPhase 3

Active, not recruiting

HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

losartan, hydrochlorothiazide

Boehringer Ingelheim

Approved

1 2

Apresoline

Novartis

Preclinical

7 3

Zebeta

Teva

Preclinical

6 4

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 5

Winrevair

Merck & Co.

Preclinical

—6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 7

Avastin

BBio-Thera Solutions

Preclinical

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension1 trial

Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria

Suspended·UUniversity Hospital, Strasbourg, France·Phase 4·NCT00369538·20 enrolled

Essential Hypertension1 trial

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02183701·715 enrolled

Hypertensive1 trial

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

Terminated·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2·NCT00388388·1 enrolled

ART1 trial

Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan

Not yet recruiting·RRESnTEC, Institute of Research·N/A·NCT06491940·234 enrolled

Blood Pressure Monitoring1 trial

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00274638·805 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for losartan, hydrochlorothiazide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — losartan, hydrochlorothiazide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for losartan, hydrochlorothiazide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

losartan, hydrochlorothiazide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension1 trial

Essential Hypertension1 trial

Hypertensive1 trial

ART1 trial

Blood Pressure Monitoring1 trial

References

Drug Info

Quick Facts

Related News